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Asn   Asparagine 
B3gnt1-5  β1,3-N-acetylglucosaminyltransferase 
CAZy   Carbohydrate-Active enzymes (classification system for GTs) 
Cer   Ceramide 
Dol-P   Dolichol-phosphate 
ER   Endoplasmic reticulum 
Fuc   Fucose 
GAG   Glycosaminoglycan 
Gal   Galactose 
Gal-Cer  Galactosylceramide 
GalNAc  N-acetylgalactosamine 
Glc   Glucose 
GlcA   Glucuronic acid 
Glc-Cer  Glucosylceramide 
GlcNAc  N-acetylglucosamine 
Gn-RH neurons Gonadotropin-releasing hormone 
GPI   Glycophosphoinositol 
GT   Glycosyltransferase 
HBGA   histo-blood group antigens 
Lac-Cer  Lactosylceramide 
Lex   Lewis x antigen 
LOS   Lipooligosaccharide 
Man   Mannose 
NV   Norwalk virus 
OB   Olfactory bulb 
OE   Olfactory epithelium 
PCR   Polymerase chain reaction 
PTM   Post translational modification 
RBC   red blood cell 
Ser   Serine 
Sia   Sialic acid 
SGGL   Sulfoglucuronylglycolipids 
SSEA   Stage specific embryonic antigens 
Thr   Threonine 
UDP   Uridine diphosphate 
VNO   Vomeronasal organ 
Xyl   Xylose 
 
* All abbreviations used are found in their complete forms the first time they are used in 
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1. Thesis summary  
Glycosyltransferases (GTs) are enzymes which catalyze the synthesis of glycans on 
various biological substrates. As modifiers of lipids and proteins, in or outside of the cell, 
glycans direct and coordinate intra- and intercellular communication. In addition glycans 
are often the first molecules within an organism to come into contact with invading 
pathogens and act as docking or entry ports. Whether as structural modifiers or signaling 
molecules, glycans play an essential role in a wide variety of biological processes. So far 
much of what is known GTs stems from in vitro biochemical assays or cell culture 
experiments. In an effort to gain a better understanding of these enzymes and the 
processes they influence in vivo data are necessary. The availability of murine embryonic 
stem cells makes the genetic manipulation of mice possible, and allows the targeted 
mutants to serve as mammalian model organisms in order to study specific genes.  
 
In this study two genes belonging to the β1,3-N-acetylglucosaminyltransferase (B3gnt) 
family  were disrupted in the mouse. The B3gnt gene family encodes GTs which catalyze 
the addition of N-acetylglucosamine (GlcNAc) to terminal galactose (Gal) or N-
acetylgalactosamine (GalNAc) on specific substrates in the β1,3 bond configuration. To 
this end, two mouse strains with targeted deletions for the B3gnt1 and B3gnt5 were 
created and examined. Previous investigations in the wildtype mouse showed the 
expression of B3gnt1 is ubiquitous while B3gnt5 reveals a more restricted expression 
pattern. In vitro enzyme activity assays of β3GNT1 and β3GNT5 showed they had very 
different acceptor substrate specificities. β3GNT1 has been described as a enzyme able 
to modify terminal Gal  on N-glycans, O-glycans, glycolipids, and glycosaminoglycan 
chains in all tissues. The activity of β3GNT5 was limited to the elongation of lacto-series 
glycolipids in a set of select tissues such as the placenta, testes, and spleen. β3GNT5 
expression was also documented in the developing embryo. The following study 
describes two mice missing GTs with similar catalytic activity with markedly different 
phenotypic effects. 
 
Generally, we expected a more pronounced phenotype detectable in the B3gnt1 null mice 
than in the B3gnt5 mice due to its ubiquitous expression. For this portion of the study an 
existing B3gnt1 null mouse line was used to examine phenotypic effects caused by the 
lack of B3gnt1. Contrary to what we expected, the disruption of B3gnt1 showed no overt 
physical phenotype. Upon closer examination with collaborators we were able to show 
1
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that there was some impaired olfactory development. Breeding the null animals was 
almost impossible. Investigations into the fertility of these null animals followed. The low 
fertility rate of male mice was finally linked to impaired male sexual interaction with 
ovulating females and the data collected used to create the first manuscript found in this 
dissertation.  
 
The second targeted mutant mouse was completed during the course of this project. A 
targeting vector was constructed and electroporated into murine embryonic stem (ES) 
cells. These clones in turn were used to reproduce two independent chimeric males 
which both exhibited germ line transmission of the null allele. Examination of the role of 
the β3GNT5 was cut short due to its effects on early embryonic development. 
Unfortunately, the disruption of this glycolipid modifying enzyme resulted in early 
embryonic death of the mice. We were not able to detect mice with homozygous null 
mutation as early as the blastocyst stage.  The second manuscript describes the results 
obtained from this second study. 
2
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Zusammenfassung 
Die katalytische Funktion der Glykosyltransferasen (GT) ermöglicht die Modifikation 
von verschiedenen biologischen Substraten mit Glykanen. Angehängt an Proteine und 
Lipide können Glykane komplexe Vorgänge innerhalb sowie ausserhalb der Zelle 
regulieren und beeinflussen. Glykane sind auch oft die ersten Moleküle, welche mit 
Mikroorganismen in Kontakt kommen, und werden deshalb als Andock- oder als 
Eingangstellen benutzt. Aufgrund dieser diversen Rollen, die von strukturellen 
Modifikationen bis hin zur Signaltransduktion  reichen, nehmen die Glykane eine 
essentielle Rolle in biologischen Abläufen ein. Um die GT und die Vorgänge, die von 
diesen Enzymen abhängig sind, in vivo besser zu verstehen und zu beschreiben, bietet sich 
die Maus als ideales Säugetier-Modell an. Seit embryonale Stammzellen von Mäusen 
verfügbar sind, kann man diese nutzen um spezifische Gene gezielt zu mutieren und zu 
untersuchen.  
 
In dieser Studie wurden zwei Mitglieder der β1,3-N-acteylglukosaminyltransferasen 
(B3gnt) Gen-Familie in der Maus untersucht. Die B3gnt Gen-Familie codiert mehrere GT 
welche die Modifikation einer terminalen Galaktose (Gal) oder N-acetylgalalaktose 
(GalNAc) mit einem N-acetylglukosamin (GlcNAc) katalysiert und in der β1,3 
Konfiguration verbindet. Mauslinien wurden hergestellt, in welchen die Gene B3gnt1 und 
B3gnt5 gezielt zerstört wurden. Die zwei resultierenden Linien wurden dann auf auffällige 
Phänotypen untersucht. Frühere Studien zeigten, dass B3gnt1 ubiquitär in Organen von 
erwachsenen Mäusen exprimiert wird. Weitere in vitro Analysen zeigten, dass das 
β3GNT1 Enzym alle N-und O-Glykane, Glycolipide, sowie Glycosaminoglykane als 
Substrat verwenden kann.  Das Expressionsmuster des B3gnt5 Genes ist restriktiver, da 
dessen Aktivität sich auf Glykolipide der Lacto-Serie beschränkt. Und diese Expression 
ist nur in ausgewählten Organen, wie die Hoden, Plazenta, und die Milz nachzuweisen. 
Ausserdem konnte man B3gnt5 in mehreren Entwicklungsstadien von Mausembryos 
nachweisen. Die Untersuchungen in dieser Arbeit beschreiben die zwei Maus Linien und 
die unterschiedlichen Folgen, welche die Ausschaltung der beiden Gene verursachen, 
auch wenn die Donor- und Substratspezifitäten der beiden Gene ähnlich sind.  
 
Generell erwartet man  beim Ausschalten von Genen, die ubiquitär exprimiert sind, einen 
ausgeprägten Phänotyp. Im ersten Teil dieser Arbeit wurde eine bereits existierende 
Mauslinie ohne aktives B3gnt1 Gen untersucht. Im Gegensatz zu den aufgrund des 
3
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Expressions- und Aktivitätsmuster des Gens erwarteten Auswirkungen fiel der Phänotyp 
vergleichsweise mild aus. Durch gezielte Untersuchungen kamen wir zum Schluss, dass 
die Tiere eine Missbildung des olfaktorischen Organs aufweisen, welche während der 
frühen Entwicklung auftritt. Das Züchten der homozygot-null Tiere erwies sich als 
äusserst schwierig. Die niedrige Fruchtbarkeit der männlichen Mäuse wurde als mögliche 
Langzeitfolge der olfaktorische Störung interpretiert. Im ersten Manuskript wird 
beschrieben, wie gezeigt wurde, dass die Männchen keine sexuellen Interaktionen mit 
ovulierenden Weibchen anstreben. Dies wurde auf ein fehlendes Erkennen der Weibchen 
in den Verhaltenstests zurückgeführt. 
 
Die zweite Mauslinie wurde als Teil dieser Arbeit hergestellt. Mit Hilfe eines Vektors, 
welcher gezielt mit dem B3gnt5 Gen rekombinieren kann, wurden mehrere heterozygote 
embryonale Stammzelllinien kreiert. Zur Herstellung eines transgenen Tieres konnten 
diese Klone in einem weiteren Schritt in Mausblastozysten eingepflanzt werden. Zwei 
unabhängige heterozygote Männchen, welche das zerstörte B3gnt5 Allel weitervererben 
konnten, resultierten aus erfolgreich rekombinierten Blastozysten. Leider konnten keine 
homozygot-null Tiere, welche kein aktives B3gnt5 Genes tragen, gezüchtet werden. Das 
fehlende Gen führte zum Tod in einem sehr frühen embryonalen Stadium. Das zweite 
Manuskript schildert die Resultate, die während diesem Teil der Arbeit gewonnen 
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3. Project Aims 
 
1.  The B3gnt1 null mouse 
The primary phenotypic examinations in the B3gnt1 null mouse in this study were to 
describe and characterize the defects relating to the null animals’ inability to procreate. 
Additionally, there was a shift in the Mendelian distribution of the null allele in the 
offspring obtained from heterozygous matings. The possible link between these two 
observations due to the effects of imprinting was also considered. In initial studies we 
were able to show that null males were not able to father progeny with wildtype female 
counterparts. Consequently we investigated parameters surrounding male murine 
reproductive capacity. This included the following: 
 
1. Morphology and motility of null sperm 
2. Sperm number 
3. Ability of males to plug estrous females 
4. Number of sperm ejaculated, collected from plugged females 
5. Sperm-egg interaction and the sperm acrosome reaction 
6. sperm migration in the uterus following mating 
7. tracking the null allele via genotyping at various embryonic stages to check 
for imprinting 
8. time course studies in vitro with eggs from wildtype mothers and either null 
or wildtype sperm 
9. Behavior studies with wildtype vs. null males with estrous females 
10. Comparison of null male behavior towards estrous females and males 
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2.  The B3gnt5 null mouse 
In a second study we aimed to examine the role of the B3gnt5 gene and the glycolipids 
β3GNT5 modifies. To this end we prepared a targeting construct which upon correct 
recombination disrupted the coding exon with a neomycin resistance selection marker. 
Four separate embryonic stem cell (ES) clones were obtained with the correct insertion. 
Two chimeric founder males were obtained which exhibited germ line transmission of the 
null allele. Heterozygote mating of these mice never gave rise to homozygous null 
offspring. The complete lack of the B3gnt5 gene was lethal to the embryo. Embryos at 
various stages of development were genotyped with PCR in an effort to determine the 
exact time of death. This study included the following experiments: 
 
1. Creation of a heterozygous ES cell line for injection into murine blastocysts 
2. Creation of founder males with germ line transmission of the null allele 
3. Crossing heterozygous animals for the production of a null line 
4. Genotypic analysis of developing embryos to determine time of death 
5. in situ studies with wildtype embryos to show early embryonic expression of 
B3gnt5 mRNA 




1. Basic concepts in mammalian glycosylation 
 
Glycosylation refers to the modification of macromolecules like proteins and lipids by 
adding glycans (poly- or oligosaccharide chains), which in the case of proteins is a 
posttranslational modification (PTM). Unlike phosphorylation, acetylation, or 
ubiquitination which link specific functional groups or proteins to a protein, the addition 
of glycans is highly diverse and introduces complexity to the protein which is unmatched 
by the other PTMs. Even though there are less than ten monosaccharide units used to 
create glycans in mammals, the variation they achieve is unsurpassed by any other 
biological modification. The quantity and individuality of glycan chains is afforded by 
their structural variation and the versatility of the glycosidic linkages which connect the 
monosaccharides. 
 
The unique structure of the monosaccharides offers first insights to their diversity as 
polymers. Cyclic representations of the most common mammalian monosaccharides are 
depicted in figure 1 with the carbons numbered according to the chemical nomenclature. 
With the exception of xylose (Xyl) and sialic acid (Sia) they are six carbon sugars or 
hexoses. Consequently Xyl and Sia can participate in fewer or more linkages with other 
monosaccharides than the other hexoses, respectively. Chemically, the monosaccharides 
are aldose (–CH=O) or ketose (–C=O) units depending on the functional group they 
contain. The main mammalian monosaccharides considered here are all aldoses. 
Monosaccharides in their linear configurations have more than one chiral center and can 
be divided into two different forms. The D or L form describes the orientation of the 
asymmetric carbon farthest away from the aldehyde functional group. As shown in figure 
2A, the D and L configurations are mirror images of one another. D and L can only 
describe differences inherent to monosaccharides in their linear conformation. These two 
forms represent non-superimposable molecules and are thus distinct carbohydrates. In 
nature, monosaccharides can be found in their D and L-forms, but the D-forms 
predominate in mammalian glycosylation reactions. Only fucose (Fuc) is used in its L-
form. Finally, since monosaccharides can exist as rings (fig. 2A) the carbonyl carbon 
becomes an additional asymmetric center (fig. 2B). This carbon is termed anomeric and 
gives rise to α and β stereoisomers due to the two ways in which the hydroxyl group can 
bind to this carbon. Analogously to the D and L configurations, the hydroxyl groups are 
  7
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mirror images of one another. They can either face the same (α) or opposite (β) side of 












Figure 1: Mammalian monosaccharide structures and common abbreviations. Hayworth projections of the 
nine main monosaccharide units used to synthesize mammalian glycans. 
 
The diversity in linkages between two sugars based on anomericity is one of the ways in 
which structure will relate to function and utilization of sugar molecules by mammals.  A 
common example of this is the difference between the two glucose (Glc)- based 
polysaccharides cellulose [Glc(β1-4)Glc]n and starch [Glc(α1-4)Glc]n.  Their different 
linkages render them completely different in their rigidity. While starch is a linear 
polymer made up of short Glc chains which are easily accessed as a quick energy source, 
cellulose polymers are long and dense making them very rigid and ideal for structural 
reinforcement. Moreover, while humans readily metabolize starch due to the availability 
of α-amylase, they cannot digest cellulose as a source of Glc because they lack β-
glucosidase Not only can two sugars be connected in two unique ways and with several 
hydroxyl groups, but they can also branch. This means that one sugar moiety may bind 
up to five monosaccharides each of which can be extended independently leading to very 
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Figure 2: Properties of the monosaccharides (A) D and L configurations of Glc. The mirror images represented 
by these two configurations make them biologically distinct. Both D and L isomers can be further defined when 
they exist as cyclical carbohydrate structures. C-1 becomes an additional source of stereoisomerism and allows 
for the synthesis of either an α or β configuration of cyclic Glc. (B) Formation of a cyclic hemiacetal from a linear 
monosaccharide unit. The availability of α or β cyclic hemiacetals diversifies the way in which monosaccharide 
units can bind to one another. The orientation of the hydroxyl group on the C-1 chiral carbon dictates how one 
monosaccharide can link to another. The figure shows D-Glc with the hydroxyl group in such an orientation that it 
can synthesize either a 1,3 or a 1,6 linkage with another monosaccharide. 
 
In addition to their intrinsic structures, glycans can be defined according to the molecules 
they modify into various classes of glycoconjugates. Currently there are seven classes of 
mammalian glycosylation described (fig 3).  The most abundant is the N-glycan class (for 
review see [1, 2]). These are asparagine (Asn)- linked glycans found on proteins whose  
Asn-N-acetylglucosamine (GlcNAc)2- Mannose (Man)9-Glc3 intermediate core is 
modified in the endoplasmic reticulum (ER) and consequently in the Golgi apparatus. 
The resulting Asn-GlcNAc2  -Man3 structure is then further modified in the Golgi 
apparatus. O-glycans are linked to a serine (Ser) or threonine (Thr) residue on proteins. 
Currently, six different monosaccharides have been implicated in the initiation of the O-
glycans. The most common O-glycan is an extension of N-acetylgalactosamine 
(GalNAc)-Ser/Thr which is usually initiated in the cis-Golgi apparatus (for review see [3, 
4]). The modification of Ser/Thr with Man or Fuc occurs in the ER [5, 6]. Glc residues 
can also be found attached to Ser/Thr. Even though this modification has been observed 

































































































































biosynthetic location continues to elude researchers [7, 8]. Historically, it was believed 
that glycosylation was limited to the ER and the Golgi apparatus. However, nuclear and 
cytoplasmic glycosylation have been documented also [3, 9]. In fact, O-linked GlcNAc 
may be one of the most common glycosidic modifications found in cells and can be 
synthesized in the cytoplasm or nucleus. Finally, in collagen, hydroxylysine can act as a 
substrate for O-glycans. In this case, galactose (Gal) is added to hydroxylysine in the ER. 
 
Glycans are not only used to directly decorate proteins, but can also be found attached to 
lipids to form glycolipids (for review see [10, 11]), or linked to phosphoinositol to create 
glycosylphosphoinositol (GPI) anchors (fig. 3) (for review see [12]). Glycolipids are 
initiated when Glc or Gal is added to ceramide (Cer) in the cis-Golgi compartment. 
Further elongation of this structure can continue in the Golgi apparatus. GPI anchors 
replace the C-terminus of the proteins they modify. The carboxyl-terminal signal initiates 
its replacement by cleaving itself from the protein allowing for substitution with the GPI. 
The GPI and provides an anchor point for these proteins into the membranes. GPI 
anchors are presassembled are pre-synthesized on the cytosolic face of the ER, while 
their transfer to proteins occurs on the luminal side of the ER [13]. Finally, 
glycosaminoglycan (GAG) chains are unbranched repeating units of disaccharides often 
found sulfated (for review see [14]). They attach covalently to proteoglycans in the ER or 
the cis-Golgi compartment. One of the simplest GAG chains is the disaccharide 
hyaluronic acid which can also be found in an unbound form in high concentrations in 
skin, skeletal tissue, and umbilical cord (for review see [15-17]). Contrary to what we 
know about glycan biosynthesis, hyaluronic acid is synthesized at the plasma 
membranerather than in the Golgi apparatus [13]. GAG chains are otherwise almost 
exclusively initiated and elongated in the Golgi apparatus. So far, the only ER-dependent 
step identified in GAG synthesis involves the addition of Xyl to its proteoglycan 
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Figure 3: Seven known classes of mammalian glycosylation. 
Generally glycans can be divided into two functional classes comprising physical or 
modulator functions, and secondly recognition or ligand functions. As structures, glycans 
can act as barriers or biological scaffolds. The extracellular matrix, for example, is largely 
made up of proteoglycans [14, 19] and collagen [20] which can alter the phenotypes of 
cells in vivo and in vitro. Without glycosylation, barriers between single cells and various 
tissues and organs would be very different as they would only have the properties 
afforded by proteins and lipids. Carbohydrate chains can bind water molecules very 
effectively. This interaction with water molecules forms gels which can act as a protective 
layer within an organism. In addition to being structural modifiers, glycans  influence the 
tertiary structure of proteins such as nerve growth factor receptor or CD2 [3, 21-23]. 
Moreover, glycans can ‘mask’ otherwise immunogenic antigens or epitopes protecting 
pathogens from the host immune system [24]. For example, HIV has a heavily 
glycosylated protein (gp120) on its surface which has 24 N-glycosylation sites. These 
sugars make up more than 50% of its mass and serve to shield the virus from immune 
recognition and antibody attack [25, 26]. However, the protective functions of glycans do 
not only serve invading pathogens. High molecular weight glycoproteins like the mucins 
are protected from protease activity via their dense O-glycans in tandem repeat domains 
[27, 28]. Glycans also give mucins their effective function as coating layers protecting 
surfaces like the bladder [29] or the oviduct [30] from damage. Finally, O-glycosylation 




The role of glycans as ligands can be further subdivided into intracellular and intercellular 
or extracellular recognition and interactions. In their intracellular functions, glycans can 
act as signals or recognize intracellular ligands. One critical intracellular signaling event 
dependent on glycans is glycoprotein folding and the action of chaperones such as 
calreticulin and calnexin. These chaperones make use of a lectin-like interaction with 
glycan structures on N-glycosylated proteins which mark them for folding modifications. 
Calreticulin and calnexin will only interact with the monoglucosylated Man core [32-34] 
(fig. 4). Events surrounding intracellular trafficking can also be dependent on glycans for 
recognition interactions [35]. The Man-6-phosphate receptor is perhaps the most studied 
structure in intracellular trafficking. Man-6-phosphate marks proteins for sorting to the 
lysosomes [36, 37]. Endogenously controlled cell surface signals like desialylated Gal or 
GalNAc glycans have been shown to act as ligands for the asialoglycoprotein receptor 






























Figure 4: Interaction of chaperone molecules with glycans on the surface of glycoproteins. The monoglucosylated 
glycan acts as a ligand receptor for the chaperones Calreticulin (CRT) and Calnexin (CNX) in the ER. The 
glycoprotein then enters the ER-Golgi intermediate compartment (ERGIC) via ERGIC-53, a membrane lectin that 
acts as a cargo receptor for glycoproteins leaving the ER and entering ERGIC. (Adapted from [34]) 
 
Extracellular interactions involving glycans refers to communication with symbionts or 
invaders. Some pathogenic invaders try to avoid recognition by the immune system via 
molecular mimicry. In this context, mimicry refers to a pathogen blending with its host 
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surroundings by adopting or expressing similar glycan moieties to those found on host 
cell surfaces. This can have dire consequences when the host does recognize the invader 
as a threat and mounts an immune answer which also recognizes host glycans and leads 
to autoimmunity. One autoimmune disease which affects the peripheral nervous system 
is Guillain Barre Syndrome (GBS). GBS was first described by Guillain and his 
colleagues in 1916 before much was known about the molecular mechanisms used by the 
human immune system [41]. Later, it was observed that some patients suffering from the 
disease were often infected with the Campylobacter jejuni bacteria preceding the onset of 
GBS [42]. Experiments showed that molecular mimicry of C. jejuni’s lipooligosaccharides 
(LOS) to GM1 gangliosides, a glycolipid, expressed in the nervous system (fig. 5). This  
causes the immune system to produce IgG antibodies against this specific glycan 
structure [42-44]. As a result the gangliosides in the nerves are attacked by the host 






























Figure 5: Molecular mimicry. The LOS chains on C.jejuni mimic those of the GM1 glycolipids found in the 
peripheral nervous system. The similarity of these two structures elicits an immune response causing GBS. 
(Hep: heptose) 
 
Alternatively, carbohydrates on host cell surfaces may be utilized as binding sites for 
certain pathogens. Many viruses use the carbohydrates expressed on cell surfaces as viral 
entry receptors. Often, these entry receptors are negatively charged GAGs or heavily 
sialylated glycans [45]. Influenza viruses have been shown to recognize endogenous Sia 
[46, 47]. Avian influenza A infects cells carrying the α2,3 Sia which it uses as a ligand [48-
50]. Human influenza A  has been shown to bind α2,6 linked Sia which is abundantly 
available in the human respiratory tract [49] making this an ideal site for infection. The 
influenza viruses use a hemagglutinin (HA) protein receptor to bind these specific Sia 
ligands. The genome of the influenza virus mutates frequently allowing them to alter 
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their HAs specificities. The resulting mutated HA protein effectively binds a new 
receptor. This allows the viruses very efficient adaptation to new ligands and is believed 
to be responsible for interspecies crosses causing past global flu pandemics [51]. 
Genomic analysis of the HA5 subunit in avian Influenza A shows that changes in just a 
few amino acids can alter its specificity from α2,3 Sia to α2,6 Sia [52, 53] rendering it 
pathogenic to human cells. Finally, cell surface glycans can be used by other viruses as 
recognition or entry receptors. It is an interaction with host cells that is available viral 








2. Structure, function, and nomenclature of eukaryotic glycosyltransferases 
 
Glycosyltransferases (GTs) catalyze the formation of glycosidic linkages needed to 
connect monosaccharides together or to their substrates. GTs assume different structures 
depending on their intracellular location which include the nucleus, the ER, the cytosol, 
or the Golgi apparatus; the latter being where both the enzymes examined in this study 
are localized. GTs generally add monosaccharides provided by high energy nucleotide 
sugars to an acceptor molecule; i.e. another sugar or a biological substrate as shown in 
figure 6. These high energy nucleotide sugars are the products of phosphorylated sugars 
and nucleotide triphosphates (NTP) like uridine triphosphate (UTP). As a result of the 
reaction, UTP loses a phosphate leading to UDP-monosaccharides which can be used in 
glycoconjugate biosynthesis. Nucleotide sugars are transferred to the ER or Golgi 
apparatus via nucleotide sugar transporters which are electroneutral antiports (fig. 6).   
 
GTs are commonly defined according to their donor and acceptor substrates. For 
example, GTs that catalyze the attachment of a βGlcNAc residue to another 
monosaccharide is termed a βGlcNAc-transferase. Additionally, the carbon of the 
acceptor and hydroxyl group of the donor sugar occupied by the glycosidic linkage are 
used to categorize GTs. Hence, a β1,4 GT catalyzes the linkage of the β anomeric carbon 
of the donor monosaccharide to the C-4 hydroxyl group of the acceptor glycan. GTs that 
catalyze the same linkage between two sugars are grouped into functional families. 
Different members of the same family are numbered, i.e. β1,3GlcNAc-transferase -1, -2, 
-3, etc. GTs with the same catalytic donor and acceptor glycans often differ in the 
biological substrates they act on (protein, lipid, GAG, etc). Different family members 
may also be defined when the GTs are simply expressed in an organ- and/or 













































Figure 6: Subcellular localization of GT reactions: The monosaccharide donors are shuttled into the Golgi via 
nucleotide sugar transporters. The GTs which are anchored into the Golgi apparatus membrane catalyze the 
addition of monosaccharides from donor nucleotide sugars to their acceptor substrates. The monosaccharide is 
released from its nucleotide sugar donor, and one of its available hydroxyl groups is transferred to an available 
carbon acceptor which will be dictated by the specificity of the GT. The resulting linkage is hence dependent on 
both the specificity of the GT and the availability of donors and acceptors. 
 
In keeping with their functional diversity, GTs exhibit relatively high variation in their 
primary sequences. The classification of GTs has undergone multiple adaptations to keep 
up with the newest information about their constituents. Today, the Carbohydrate-Active 
enZymes (CAZy) classification predominates (for review see [58, 59]). In this system, the 
GT families are grouped according to both their structural and catalytic properties as 
described above. The Golgi GTs share significant secondary structural homologies. They 
are type II transmembrane proteins with a single transmembrane domain. This domain is 
flanked by a short cytosolic amino-terminal end and a larger carboxy-terminal part in the 
lumen of the Golgi apparatus (fig. 7). This part contains a stem-region to which the 
actual catalytic domain is attached an in turn gives the enzyme its specificity. ER and 
Golgi GTs are both anchored to the membranes of these organelles. The nuclear and 
cytosolic GTs are soluble and bear some similarity to one another in their secondary 
structures [60]. Although the activity of certain cytosolic GTs have been described [61-
63], only one of these mammalian GT’s has been shown to also localize to the nucleus; 
an O-GlcNAc transferase [62, 64, 65]. However, like their ER and Golgi counterparts, 

















































Figure 7: Basic structure of a Golgi GT. The GT is anchored to the Golgi membrane via its transmembrane 
domain. The catalytic site faces the lumen of the Golgi, while only a small portion of the N-terminus is in the 
cytoplasm. 
 
The nomenclature described above cannot apply to GTs initiating a glycan on a 
biological substrate. These special GTs are often named for the glycan products they 
initiate, i.e. glucosylceramide synthase or the different Ser/Thr modifying GTs in O-
glycosylation. In contrast to classical elongating GTs in the Golgi apparatus, the donor 
substrates may be nucleotide sugars, lipid activated monosaccharides, or preassembled 
lipid linked glycans. For a more complete review of GTs initiating glycolipids, O-glycans, 
GPI anchors, and N-glycans the reader is referred to references [3, 11, 12, 66]. 
 
Investigations have shown that linkage types (i.e. β1,3 or α2,3) commits to structural 
conservations among different GTs. Consequently, sequence homology among these 
GTs in their catalytic domains is not uncommon. As a result a β1,3Gal- transferase 
shares more homology with a β1,3GlcNAc- transferase than with a β1,4Gal- transferase 
[67]. This suggests that there might be genetically similar sequences particular to a 
specific linkage between two monosaccharides (i.e. β1,3). However, the monosaccharides 
involved may vary in their donor or acceptor roles. Sia and Fuc transferases are 









3. The β1,3GlcNAc-transferase family 
 
The β1,3GlcNAc-transferase (B3gnt) family is made up of genes which encode GTs that 
catalyze the addition of β1,3GlcNAc onto a Gal or GalNAc. The mammalian B3gnt gene 
family currently has 5 members with confirmed functions and one (the ignt) whose 
protein function is under debate. All known B3gnt genes and the proteins they code for 
are listed in Table 1 along with their chromosome locations, acceptor and substrate 
specificities, and tissue expression profiles. All the enzymes encoded for in this family 
except β3GNT6 add a GlcNAc to a Gal leading to the (GlcNAc β1,3- Gal β1,4) product. 
This product is termed a lactosamine or a polylactosamine when multiple units are linked 
together on a substrate. β3GNT6 initiates core 3 O-glycosylation by adding a 
β1,3GlcNAc to a an O-GalNAc.. As noted in Table 1, lactosamines are found on all 
classes of glycoconjugates. Those enzymes listed in bold are the focus of this study. 
 





















Fetal brain, all adult 
tissues 
 




























































Mucins in stomach, 
colon, and small 
intestine 
1 The same gene/enzyme is described in both studies under different names. Here the enzyme will be 
called B3gnt1 and the protein β3GNT1. 
 
 
The iGNT was the first enzyme with lactosamine synthase activity described [68]. It was 
found to be especially active on blood group antigens. Its name derives from the 
embryonic i-antigen, which changes to its adult form, the I-antigen, later in development 
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(fig. 8).  Although the gene described has a unique sequence, the lactosamine or 
polylactosamine synthase activity ascribed to iGNT could not be substantiated when tested 






















Figure 8: Synthesis of the i and I-antigens 
 
β3GNT1 is the enzyme with the broadest substrate specificity and tissue expression 
profile discovered thus far [69, 70] (fig. 9). This Golgi enzyme not only elongates glycans, 
but it has been shown to initiate and elongate polylactosamines in particular [69]. As part 
of this study we obtained mice with a targeted disruption of the B3gnt1 gene. Our 
phenotyping experiments showed that this gene regulated lactosamines or 
polylactosamines on various biological structures including parts of the brain and T-cells. 
The polylactosamines have previously been shown to regulate T-cell activity [71] and 
developmental antigen regulation on blood cells [72]. In addition, lactosamine structures 
under the control of β3GNT1 have been implicated in neuronal processes such as axon 
guidance in the olfactory epithelium (OE) and vomeronasal organ (VNO) [73] and play a 
role in directing the migration of gonadotropin-releasing hormone (GnRH)-neurons in 










Figure 9: β3GNT1 elongates lactosamine chains on various glycan substrates. Β3GNT1 is the rate limiting 
enzyme in the formation of polylactosamine chains. These chains can be found on N and O-glycans, on GAG 























Little is known about the activity of the β3GNT3 and β3GNT4 enzymes. Both were 
discovered in a study  in which cDNA from human gastric mucosa and from the 
neuroblastoma cell line SK-N-MC were screened for B3gnt1 homologs [70]. Both were 
shown to contain shared motifs found in members of both the B3galt family and the 
B3gnt family. They are distinguishable from β3GNT1 by their substrate specificities 
which for β3GNT3 includes core-1 O-glycosylation elongation. Recombinant expression 
studies revealed that β3GNT3 and 4 had the same monosaccharide substrate acceptor as 
β3GNT1, namely Gal, but that the complete substrate structure was unique. As shown in 
Table 2, β3GNT3 has high activity with lactose and lacto-N-tetraose and some activity 
on p-lacto-N-neohexose. β3GNT4 shows only limited activity on lacto-N-neotetraose. In 
addition to structural preferences, the expression profiles of β3GNT1, 3, and 4 are 
different. While β3GNT1 is ubiquitously expressed, β3GNT3 was detected mostly in the 
colon, placenta, stomach, jejunum, and high endothelial venules. β3GNT4 expression is 
limited to relatively low levels in the brain. 
 
A recent study with the core-1 elongating enzyme β3GNT3 has provided new 
information about the role of this enzyme in vivo [75]. Mice with targeted null mutations 
for B3gnt3 were examined for their lymphocyte homing capabilities. The core-1 O-
glycans serve as scaffolds for the MECA-79 antigen whose synthesis was suspected to be 
under the control of the β3GNT3 enzyme. This study showed that β3GNT3 is solely 
responsible for the core-1 extension necessary for MECA-79 expression which binds L-
selectin. The loss of MECA-79 corresponded with higher in vivo rolling velocities of B 
and T lymphocytes due to this lost interaction with L-selectin. Moreover, there were 
decreased numbers of B lymphocytes in the B3gnt3 null animals although the total 












Table 2: Preferred substrates for β3GNT1, 2, and 3. (Adapted from [70].) 
Substrate Structure β3GNT1 β3GNT3 β3GNT4
Lacto-N-
neotetraose (LNnT)
Galβ1-4GlcNAc β1-3Galβ1-4Glc 100a 100 100 
Lactose Galβ1-4Glc 67 235 33 
Lactosamine Galβ1-4GlcNAc 96 0 4 





ND 45 0 
a Activities are expressed as a percentage of the activity for pyridylaminated (a fluorescent labeling for sugar 
chains using 2-aminopyridine) LNnT . 
 
β3GNT5 represents a distinct member of the β3GNT family which is responsible for 
initiating lacto-series (Lc3) glycolipids (fig. 10) [76, 77]. The Lac-Cer glycolipid core 
serves as a substrate for numerous glycolipid structures. Among others, the lacto-series 
(GlcNAc β1-3- Gal β1-4) unit acts as a scaffold for the synthesis of blood group 
antigens. These are essential for the formation of the A, B, and O antigens  and some of 
the stage specific embryonic antigens (SSEA) [66]. β3GNT5, also a Golgi GT,  was 
found to be highly expressed in adult murine spleen, placenta, and to some degree in the 
testes [76].  In situ analyses revealed broader expression of the enzyme during embryonic 
development compared to its adult profile [76] including the central nervous system, 

























Figure 10: Overview of glucosylceramide glycolipid biosynthesis. β3GNT5 catalyzes the initiating step for the 











identified an ortholog for Lc3 synthase gene [78, 79]. Both studies showed that B3gnt5 
was expressed during embryonic development. Notably, the gene seems to be important 
for lens development in the zebrafish. This was similar to findings in the mouse where it 
was also found in the developing eye [76]. An in vivo analysis of B3gnt5 in the mouse 
comprises the second part of this study. We targeted the B3gnt5 gene by introducing a 
neomycin resistance cassette into the single coding exon of B3gnt5 in order disrupt its 
transcription, thus enabling the investigation of B3gnt5’s physiological role of this gene 
and its products in vivo. 
 
β3GNT6 activity had, until recently,  only been described for the human enzyme [80, 81] 
although a predicted murine β3GNT6 ortholog is listed in GenBank. Human β3GNT6 is 
the enzyme that elongates core-3 O-glycans [80]. Core-3 O-glycans are the result of a 
β1,3GlcNAc addition to a GalNAc (β1,0) -Ser/Thr (fig. 3). Core-3 O-glycans (figure 11) 
are structural precursors of more than half of the mucins found in all parts of the 
intestines [82]. Quantitative PCR verified high expression in the stomach, colon, and 
small intestine, all areas in which mucins are found in high concentrations. Additional 
studies showed that β3GNT6 was down-regulated in gastro- and colorectal cancers [81].  
Furthermore, expression of β3GNT6 in tumor cells injected into nude mice was able to 
lower the metastatic migration of tumor cells [81]. Glycoepitopes have long been studied 
as possible cancer markers [11, 83]; the core-3 O-glycans offers just one example of how 
glycans can modulate cancer cells and their effects on the host. Recently, the disruption 
of B3gnt6 showed that this gene does code for the protein responsible for core-3 O-
glycan elongation in mice by An et al. (2007) [84]. In addition the authors were able to 
confirm the importance β3GNT6 modified core-3 O-glycans in preventing susceptibility 
to colorectal tumors and colitis in the murine model. This parallels findings observed in 

































Figure 11: Core 3 biosynthesis of O-glycans (taken from [81]). The activity of β3GNT6 is limited to O-glycans. 
Here β3GNT6 is adding the GlcNAc to a GalNAc acceptor rather than to a Gal. This is the only family member with 
an acceptor other than Gal. 
 
 
The B3gnt gene family encodes enzymes involved in the modifying Gal or GalNAc with 
β1,3GlcNAc. The lactosamines resulting from the activities of β3GNT1-5 have been 
detected on all the known glycoconjugates classes. Both these substrates and the activity 
of the B3gnt family of genes can fall under developmental, expression, or tissue specific 
control mechanisms. Since the catalytic activities and donor- acceptor substrate 
specificities are so similar for these enzymes, the best way to study them individually is to 
disrupt them one by one in vivo. The availability of murine embryonic stem cells provides 
a mammalian model for the analysis of these genes and their products by inactivating 
their coding regions via insertion or deletion cassettes. Results obtained will give more 
insight into the unique organ, developmental, and substrate specificity for each family 
member. We aim to detect phenotypic abnormalities resulting from the inactivated gene 
that can give us more information about when, where, and with what acceptor substrates 
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This manuscript describes the results obtained from investigations into the male fertility 
phenotype observed in the B3gnt1 null male mice. It was recently accepted for 


















































































































































































































































































































































































































































































































































Monthsa 1  2  3  4  5  Expected  Observed  Litter size 
Wildtype (n=4)  14  15  13  15  14  80  71 (88.8%)  7.5 ±2.5 






















Newborn  (NMRI)  35%  48%  17%  (n=268) 
Newborn  (C57Bl/6)  33%  51%  16%  (n=913) 
E10  (C57Bl/6)  32%  57%  11%  (n=53) 
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54









































n=4 n=4 n=3 n=5 n=4 n=4 n=3 n=5































































Figure 4 – Biellmann et al.
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Glycolipids are found throughout the plasma membranes of mammalian cells. Due to 
their ubiquitous expression, glycolipids have been linked to various cellular activities 
including trafficking, signal transduction, and inter/intracellular interactions. Glycolipid 
biosynthesis is a cascade controlled by highly specific glycosyltransferases. One of the key 
enzymes implicated in the initiation of lactoseries glycolipid biosynthesis is the β1,3-N-
acetylglucosaminyltransferase V (β3GNT5) which is coded for by the B3gnt5 gene in the 
mouse. In an effort to study the targets and effects of missing lactoseries glycolipids in 
vivo a heterozygous ES cell line was created to generate a B3gnt5 null mouse line. The 
homozygous targeted deletion of B3gnt5 led to the embryonic death of these mice. The 
data collected concerning the survival of null mice suggests that the expression of B3gnt5 
is crucial to the embryonic development of the mouse embryo. Additionally, our findings 
show that B3gnt5 transcript is detectable throughout the pre-implantation stage of murine 
development. Finally, we investigated the expression of the gene in wildtype and 
heterozygously targeted ES cells to gain insight into the role of this gene on murine ES 





The β1,3 N-acetylglucosamine transferase V (β3GNT5) has been described as a 
lactosylceramide modifying enzyme responsible for the elongation of lacto-series 
mammalian glycolipids leading to the synthesis of the Lc3 structure [1, 2]. Glycolipids are 
generally divided into two classes according to their main structural cores. Both of these 
main cores are ubiquitous. Some glycolipids, including those modified by β3GNT5, are 
built on glucosylceramide (Glc-Cer) while others have galactosylceramide (Gal-Cer) as a 
scaffold for further glycan modification. After the addition of a galactose residue to the 
Glc-Cer scaffold, lactosylceramide (Lac-Cer) results, a precursor for hundreds of 
glycolipids. Glycolipids synthesized on the Lac-Cer precursor are subdivided into three 
major classes, the ganglio-series, the globo-series, and the lacto-series (fig. 1). The 
glycosyltransferase controlling the formation of the Lc3 structure  represents the first 
modification selecting these glycolipids as lacto-series glycolipids. 
 
Glycolipids have only gained attention in the mid twentieth century [3]. Glycolipid 
research was limited due to lack of techniques available to characterize these structures at 
all, let alone their functions. As a result, elucidation of glycolipid structures per se and their 
expression profiles in vivo were the focus of many investigations, with their functions 
initially taking a back seat. Since then, glycolipids have been implicated in processes 
ranging from embryonic and neuronal development to cellular adhesion and as viral 
receptors mediating infection [4, 5]. One of the first properties attributed to the 
glycolipids was their species patterns on erythrocytes [6]. The discovery of the 
developmentally- and differentiation-specific expression of glycolipids quickly followed 
[7-9]. Here it was shown that varying glycolipid structures are expressed in the murine 
embryo from the embryo pre-implantation stages. There are several glycoepitopes and 




Collectively these are termed the stage specific embryonic antigens (SSEA) and have 
been shown to undergo rapid changes in their epitope expression [3]. SSEA-1 (also called 
Lewis X) is perhaps one of the most well characterized members of these antigens. The 
glycolipid core that gives rise to the SSEA-1 depends on the lacto-series core for its 
biosynthesis on glycolipids, which is previously modulated by β3GNT5. However, the 
SSEA-1 is a carbohydrate epitope that can be found on glycolipids, glycoproteins, and 
proteoglycans. Its function is believed to be the regulation of cell adhesion in 
embryogenesis, cell differentiation, and development of the neuronal system [7, 17].  
 
The availability of murine embryonic stem (ES) cell technology had provided a way to 
investigate the functional role of the glycosyltransferases involved in glycolipid 
biosynthesis in vivo. Studies on mice missing genes encoding glycolipid-modifying 
glycosyltransferases have displayed a wide variety of phenotypes [5, 18].  Deletion of the 
complex ganglioside (GM2/GD2) synthase gene in mice led to axonal degeneration in 
optic and sciatic nerves and decreased central myelination. This underlines the 
importance of glycolipids as mediators of cellular adhesion. When the more basic cores 
of glycolipids were examined in null mice models, the phenotypes were surprisingly 
variable. While deleting the galactosylceramide transferase gene (Cgt) had little effect on 
embryonic development, it led to numerous adult phenotypes due to the role of 
sulfatides in myelin function and stability. These included tremors, mild ataxia, and 
progressive hind limb paralysis [19]. Another group disrupted the glucosylceramide gene 
(Ugcg). Homozygous null embryos died by embryonic day (E) 9.5. Moreover, their lagging 
development was visible earlier [20].  
 
The crucial role of glycolipids in early embryonic development was also shown in a β1,3 




B3GalNAcT was later shown to be the enzyme coded by the B3galnt1 gene (Accession 
number NM_020026) controlling Gb4 synthesis [21], and the absence of this class of 
glycolipid led to pre-implantation death of the murine embryos [22]. These studies show 
the broad effect the glycolipids have on murine phenotypes, and their particular 
importance in early embryonic development. While the disruption of an entire class of 
glycolipids was certainly expected to cause severe phenotypes, the studies show that the 
time and specificity of the defects caused by missing glycolipids varies. The importance 
of functional glycolipids in early embryonic development and in adult mice has been 
shown for both core glycolipid precursors and their downstream products.  
 
Among the functions attributed to the B3gnt5 gene encoding the Lc3 synthase (β3GNT5) 
was when Chou et al. showed that it was an enzyme key to the regulation of 
sulfoglucuronylglycolipds (SGGL) in the developing nervous system [23]. The SGGL 
epitopes are expressed in a highly regulatory fashion during rat embryonic brain 
development and again postnatally [24-27]. In addition SGGLs are reactive to the 
monoclonal antibody HNK-1 which recognizes terminal nonreducing carbohydrate 3-
sulfoglucuronic acids of the glycolipids. In adult rats, B3gnt5 expression is limited to the 
Purkinje cells in the cerebellum. The developmentally regulated expression of the SGGLs 
coincides with certain cell migration and differentiation phases [28]. The effect of the 
SGGLs on neuronal development makes them prime targets for research in many areas 
including brain plasticity and neuronal deficits.  At the same time SGGLs provide us a 
new target for examining the role of glycolipid function in vivo. 
 
Further investigations into the expression of B3gnt5  revealed that the gene is highly 
expressed in spleen and placenta as well as in various organs in the developing murine 




of the lacto-series glycolipids initiated by B3gnt5, we have generated a mouse missing the 
B3gnt5 gene. Since the Lc3 substrate is the scaffold for lacto-series glycolipid elongation 
by different glycosyltransferases, the absence of this structure could provide us insights 
into its structural and functional properties. As this gene is present already in the embryo, 
its role in early murine development and differentiation was the main focus of our 






Materials and Methods 
 
Gene targeting:   
Mouse Genomic 129/Sv bacteriophage library (Stratagene), was screened with a mouse  
B3gnt5 cDNA probe. A genomic clone of 12 kilo base pair (kbp) was isolated and 
subcloned as a NotI-NotI fragment in pBluescript II. A 3.6 kbp long arm fragment from 
the coding exon for B3gnt5 was cut from the genomic sequence containing plasmid with 
a BstX I/ Xba I digest and cloned into the neomycin resistance- (neor) containing vector 
(PGKneoBPA) at the EcoR V site in front of the neor cassette. The short arm of the 
B3gnt5 coding exon was cloned into pBluescript II SK+ as a 1.7 kbp BstX I/ Nde I 
fragment at the Sma I site of the polylinker. The 1.7 kbp fragment containing pBluescript 
II SK+ plasmid was recloned into pBluescript II SK+ as a Sac II- Xho I fragment to 
obtained desired restriction sites for further modification  The orientation of the 
fragment was verified with sequencing, showing that the short arm fragment was now 
flanked by 2 Not I restriction sites. A Not I digest was done, and the 1.7 kbp fragment 
ligated into the Not I site following the poly A site for the neor cassette of the long arm 
containing PGKneoBPA vector. As a result we created a targeting vector where the neor 
sequence replaces a 745 bp stretch of the B3gnt5 coding region (Fig. 1A). Restriction 
digests were done to insure proper orientation of the fragment and sequencing of the 
genomic region flanking the neor gene were done to insure proper genomic sequence was 
in the targeting vector. The final targeting vector was 7.1 kbp in size. 10 μg of the vector 
was linearized using Sac II, and transformed into five million TC1 and R1 murine 







Disruption of B3gnt5 in ES cells and generating B3gnt5 chimeric mice:   
ES cells containing the transformed neor construct were selected for using neomycin 
(G418) (200 μg/ml) supplemented KO DMEM (Gibco) containing 15% fetal calf serum 
(Gibco), and 1000U/ml leukemia inhibitory factor (ESGRO). After several days of 
selective culture, 300 neor clones were re-cultured in 24-well plates using the same 
selective media. Primers were constructed so that the region flanking the end of the neor 
insertion and the genomic sequence were detectable as a 1920 bp fragment in the null 
allele of homologously recombined ES clones. The primers had the following sequence, 
(5’ - TAC TAC CCT GTC TAG GAG CAG TTG - 3’ and 5’- CAT CGC ATT GTC 
TGA GTA GGT GTC - 3’) and were run with an initial denaturing step at 94° C for 5 
min followed by 35 cycles of 94° C 45 sec, 52° C 1 min, and 72° C 1 min 50 sec, with a 
final elongation at 72° C 5 min. The proper recombination of the B3gnt5 allele was 
confirmed using genomic Southern blot for which a 32P labeled 0.5 kbp sequence from 
B3gnt5 genomic sequence was used as a probe. Eco RI digested wildtype and possible 
heterozygous ES clones were probed. Finally the positive clones were karyotyped using 
the standard potassium chloride method [29]. Two chimeric males resulted from the 
injection of ES cells heterozygous for the B3gnt5 allele into blastocysts derived from 
C57BL/6 mice. These males were then bred with C57BL/6 females and the resulting 
offspring were genotyped for the transmission of the null allele. Offspring resulting form 
both founder males were bred onto the C57BL/6 for 6 generations. Finally, F6 
heterozygotes were crossed in order to obtain homozygous null mice. 
 
PCR genotyping: 
To detect the B3gnt5 null allele in viable offspring, a 789 fragment containing a portion of 
the genomic and neor sequence was amplified (5’ - ACT CGT CAA GAA GGC GAT 




allele, primers amplifying a region disrupted by the neor insertion were used to amplify a 
651 bp fragment (5’ - GGC TCA AGA TGT CCT CCT CTT A - 3’ and 5’ - ACA TGG 
TCC TGT GGC AAG ATT C - 3’). These PCRs were both run with an initial denaturing 
step at 94° C for 5 min, followed by 35 cycles of 94° C 1 min, 60.5° C 45 sec, 72° C for 
40 sec, and then a final extension at 72° C for 5 min. To genotype E3.5 blastocysts, (if 
E0.5 is the time of plug detection), primers amplifying a smaller fragment of the null 
allele were used. Here, a 326 bp fragment of the neor cassette was amplified for the B3gnt5 
null allele (5’ - CAT CAG CCG CTA CAG TCA AC-3’ and 5’-CAT CAG AGC AGC 
CGA TTG TC - 3’), while the same primers used to detect the wildtype allele as 
described above (651 bp) were used. REDTaqTM (Sigma) genomic DNA polymerase was 
used to amplify DNA from blastocysts. The PCRs were run with an initial denaturing 
step at 94° C for 5 min, followed by 35 cycles of 94° C 45 sec, 63.5° C 40 sec, 72° C 25 
sec, and a final extension at 72° C for 5 min. 
 
Isolation of E3.5 and E10 Embryos:   
Pre-implantation (E3.5) and E10 embryos were collected from pregnant females. E3.5 
blastocysts were isolated by flushing of the uterine horn. Blastocysts were placed in 
gelatinized 96-well plates for 5-7 days. This allowed for the outgrowth of enough cells for 
proteinase K treatment (25 ug/ml) and direct genotyping with the primers described 
above. E10 embryos were collected individually from their placentas being careful to 
remove all maternal tissue. E10 embryos were placed in proteinase K solution 
immediately, digested O/N at 56°C and the DNA phenol chloroform extracted before 







In Situ Hybridization:   
Pre-implantation embryos collected for in situ hybridization were obtained from wildtype 
C57BL/6 matings with superovulated females. Superovulation was carried out as 
previously described [30]. Embryos were removed at E1.5 (2-4-cell stage) and E3.5 
(blastocyst stage). To obtain embryos at the 4-cell up to the morula stage, 2-cell embryos 
were cultivated in M16 media (Sigma) until the desired stage was reached. A protocol 
describing in situ hybridization conditions for whole murine embryos [31] was modified 
for our experiments as follows. All solutions were made with RNase free reagents and 
with DEPC-treated water. Embryos were fixed for one hour at RT in 4% PFA and 
washed twice in 0.1% Tween PBS (PBT). Embryos were dehydrated in increasing 
concentrations of methanol in PBT (25%, 50%, 100%) for 5 minutes each and stored in 
100% methanol until use at -20° C.   
 
Before use the embryos were rehydrated in the opposite methanol concentration order 
(100%, 75%, 25%) and then washed twice in PBT. For permeabilization the embryos 
were incubated in Radioimmunoprecipitation (RIPA) buffer (Sigma) buffer for 10 min 
and then rinsed in three changes of PBT for 5 min each. Embryos were then washed in a 
1:1 mixture of PBT/hybridization solution (supplementary data) for 10 min and then 
again in just hybridization solution. Prehybridization in hybridization solution followed at 
70° C for ≥2 h. The embryos were hybridized with either sense or antisense riboprobe 
over night in 750 ul hybridization solution at 70° C. 
 
Embryos were washed in hybridization solution followed by 3 washes in solution I 
(supplementary data) all at 70° C except the last which was at 65° C. Three 30 min 
washes in solution II (supplementary data) at 65° C followed. Embryos were cooled to 




(supplementary data) buffer. A blocking was done with 2% Boehringer’s Blocking 
Reagent (Roche, Switzerland) in MAB for 90 min at RT. Finally pre-absorbed anti-DIG-
AP antibody was added to the embryos and incubated over night at 4° C. The next day 
embryos were washed three times 5 minutes at room temperature with MAB followed by 
five 60 minute washes with MAB at room temperature. Embryos were incubated with 1x 
levamisole MAB over night at 4°C. 
 
Embryos were washed three times 10 min in fresh AP (supplementary data) buffer at RT. 
Staining was done at room temperature or 4°C for longer incubations (O/N). When 
color development was sufficient, i.e. when antisense probe gave visible signals under the 
microscope, the reaction was stopped with 2 mM EDTA in PBT. On the last day, 
embryos were post fixed in 4% PFA/ 0.1% gluteraldehyde in PBT for 1 h at RT or over 
night at 4°C and then washed twice in PBT. Embryos were washed in glycerol: PBT (1:1) 
and stored in glycerol: 2 mM EDTA in PBT (4:1). The signals observed at various stages 
of development were documented using the Zeiss Axiovet 200M microscope (Carl Zeiss 
AG, Feldbach, Switzerland). 
 
For probe preparation,  plasmid containing the cDNA sequence needed for the 
production of in situ riboprobes were available in our laboratory from previous 
experiments [1]. T7 and SP6 riboprobes were made using a DIG RNA labeling kit 
(Roche, Switzerland). Since both sense and antisense probes are on the same plasmid and 
differ only in their digests (Hind III for anti-sense and Sac I for sense) both riboprobes 
were 908 bp long. An alkaline hydrolysis followed the labeling reactions in order to 
reduce the size of the riboprobes to about 300 bp for better passage through the 





Quantitative PCR:  
Quantitative PCR (qPCR) reactions were done to check for the expression levels of 
B3gnt5 in wildtype versus heterozygous ES cell clones. Primers were designed for B3gnt5 
and an RNA polymerase gene (NP_033115) which was used as a reference marker. The 
following primers were used for the B3gnt5 gene (5’ - CAT ATA CCC ACA GAC CAG 
AG - 3’ and 5’ - CAC AGA GCT GTG CTT GAG AG - 3’) and the RNA polymerase 
gene (5’ - AGC CAA AGA CTC CTT CAC - 3’ and 5’ - GGG GTT AGG GTC ATA 
GTA GA  -3’). As the protein coding region of B3gnt5 is found in a single exon, RNA 
batches used for cDNA production were DNase treated and tested for the presence of 
DNA contamination with a standard PCR reaction. 2 μg DNA-free RNA was used to 
make cDNA using a reverse transcription kit Omniscript RT (Qiagen). 2 μl (10% of RT 
reaction) of the cDNA produced was used in the qPCR reactions with the SYBR® Green 
JumpStart kit (Sigma). The reactions were measured in MX-300P QPCR machine 
(Stratagene).  The reactions were run with an initial denaturing step of 10 min at 95° C 
followed by 40 cycles of 95° C 15 sec, 59° C 1 min, and 72° C 20 sec. A final cycle of 95° 





The targeting construct (Fig. 2) used in the electroporation of  R1 and TC1 ES cells 
from 129/SvEv mice led to the production of four independent ES cell clones which 
were heterozygous at the B3gnt5 gene locus. These independent ES cell clones were 
confirmed using both PCR and genomic Southern blot analysis. The genomic Southern 
probe distinguished between the wildtype (3 kbp) and the null allele insertion (2.3 kbp) 
(Fig. 3A) in these Eco RI digested ES clone’s DNA. Finally, the ES cells used for 
blastocyst injection were karyotyped to show they contained a complete set of 40 
chromosomes (data not shown). 
 
Properly recombined ES cells were injected into the blastocysts of C57BL/6 mice to 
produce chimeric male offspring. Two chimeric founder males were obtained. These 
males were mated with wildtype C57BL/6 females and the F1 progeny screened with 
PCR for germ line transmission of the disrupted allele as described in materials and 
methods. Both chimeric males transmitted the null allele.  Offspring positive for the 
disrupted gene were backcrossed onto the C57BL/6 background for 6 generations. All 
the heterozygous offspring obtained from the chimeric males were grossly normal.  Both 
male and females carriers of the null allele were obtained. F6 heterozygotes were then 
bred to produce null offspring. After crossing 17 independent heterozygote breeding 
pairs, no homozygous null offspring were detected (Table 1). A previous investigation 
showed B3gnt5 expression was detectable at numerous stages of embryonic development, 
especially at E11,  and in the placenta [1]. Mid-gestation embryos (E10) were isolated 
from pregnant females from heterozygous matings. (Fig. 3B). Fifty one embryos from 
seven heterozygous matings revealed no homozygous null embryos at E10 (Table 1).  
Notably, no resorbed embryos were observed during the E10 isolations. In an effort to 




uterine implantation (E3.5) at the blastocyst stage. Again, no homozygous null embryos 
were detected (Table 1) with PCR (Fig. 3B).  Our results suggest B3gnt5 expression is 
important for very early embryonic development in the mouse.   
 
Detection of the B3gnt5 transcript in various early development sages with RNA in situ 
hybridization followed. For clarity, we tested embryos of the wildtype C57BL/6 
background on which our null allele was introduced. Our investigation revealed that 
mRNA transcript of the gene was expressed as early as the 2-cell stage (Fig. 4). In fact all 
the wildtype embryos were positive for B3gnt5 at all stages tested up to the blastocyst. 
These findings suggest B3gnt5 is expressed during the pre-implantation stages of 
embryonic development might be important for early embryonic development in the 
mouse.   
 
Finally, since we could see a very pronounced staining of the inner cell mass of the 
blastocyst with in situ hybridization, we examined our heterozygous ES cells for altered 
B3gnt5 gene expression. Quantitative PCR studies were performed on cDNA reverse 
transcribed from the mRNA obtained from wildtype TC1 and R1 ES cells and their 
respective heterozygous clones. A decrease in the level of mRNA expression in the 
heterozygote ES cells points to a possible role for B3gnt5 in multipotency and 
consequently might affect early embryonic development. According to our data B3gnt5 
mRNA was detectable in wildtype ES cells, although not at an elevated level when 
compared to the house keeping gene (RNA polymerase). Our findings revealed a much 
lower level of B3gnt5 mRNA expression in the heterozygote ES cells when compared to 
their wildtype counter parts. For the R1 line, the heterozygous ES cell line showed only 
14.8% (± 3.95%, n=3) of the normal wildtype B3gnt5 mRNA expression levels. In the 




roughly 3% (± 0.21%, n=3) of what was observed in the wildtype line. The disruption of 
just one B3gnt5 allele is enough to decrease mRNA substantially. The effect of these 






Glycolipids are poorly understood biological molecules which can be found throughout 
mammalian membranes. By disrupting the B3gnt5 gene we aimed to get a better 
understanding of the functions of the lacto-series glycolipids in vivo. The mutation of this 
gene proved to be fatal for the mice, and the time point at which it causes embryonic 
death and its possible role in multipotancy was examined. Our investigations of the 
developing embryo first showed that null embryos were not detectable at E10, the day 
before significant levels of B3gnt5 had been shown in previous Northern blot 
experiments and whole mount in situ experiments [1]. This suggests the expression of 
B3gnt5 is crucial to earlier stages in murine embryonic development. Here we report that 
mice which do not express B3gnt5 die prior to the pre-implantation (E3.5) stage of 
development. Consequently, the regulation and expression of B3gnt5 is likely to be 
essential for processes prior to cell division or at the very latest for compaction at the 
morula stage. 
 
We were able to detect B3gnt5 mRNA transcripts as early as the 2-cell embryonic stage in 
wildtype murine development. Based on current information concerning the precursor 
necessary for β3GNT5 activity, namely glucosylceramide transferase (Ugcg), the early 
embryonic phenotype observed came unexpectedly. Disruption of the B3gnt5 gene led to 
a lack of blastocyst stage embryos although the Ugcg null embryos survived to E7.5-8.5. 
However, this is not the first example of such a discrepancy in the phenotypes observed 
in mice missing glycosyltransferases that are implicated in glycolipid synthesis. In their 
investigation of the effects of removing the Gb4-synthase gene (B3GalNacT), Vollrath et 
al. showed that disruption of this gene displayed a similar phenotype to the B3gnt5 null 
mutation [22]. This leads us to question the availability of alternative glycolipid, or 




in the Ugcg null mice (Fig. 5A). Alternatively, it is likely that there is another Glc-Cer 
synthase which is active enough to afford a longer survival time in the Ugcg null embryos. 
Here it should be mentioned that there are two genes with considerable homology to 
Ugcg whose activity has not yet been described in the human genome [32, 33]. Although 
these homologs have not been reported yet in mice, they could also exist.  
 
Another factor influencing the development of the developing embryo is the expression 
of maternal and/or paternal mRNA and proteins. It has been shown that certain 
maternal mRNAs can persist through to the blastocysts stage of development in the 
mouse [34, 35]. Since we could not detect a gap in the expression of B3gnt5 from the 2-
cell through the blastocyst stage of development, we cannot account for possible 
maternal RNA expression of the gene. The temporal inconsistencies displayed by 
embryonic lethality phenotypes in the glycolipid synthesis cascade may also be influenced 
by maternal or paternal expression of the genes in question. Moreover, the lack of 
blastocyst stage embryos we observed might be the result of a problem earlier in the 
fertilization cascade, for example, if the fusion of two null gametes is not possible at all. 
 
Although there is no clear upregulation of the B3gnt5 gene detectable with qPCR in 
murine ES cells, a constant level of expression is detectable. Moreover, a considerable 
drop in transcript in the heterozygous ES cell lines derived from both the TC1 and R1 
lines was detectable. Although the qPCRs do not prove B3gnt5 is important to early 
embryonic development, it does give us a quantitative indication of the severity of the 
heterozygous null phenotype. Apparently low levels of B3gnt5 are enough to ‘rescue’ the 
animal in the heterozygous background even if these are at less than 15% of wildtype. 
Other glycans whose expression has been implicated in murine embryo development are 




was shown in a recent study with the α1,3-fucosyltransferase IX null mouse (FUT9).  
Fut9 regulates the fucosylation of the SSEA-1 and was believed to the essential 
recognition glycan for the proper function of the SSEA-1 epitope. However, disruption 
of the FUT9 coding gene showed that although the  null mouse completely lack the 
SSEA-1  structures during early embryonic stages, these mice develop normally [17]. 
Interestingly, the LC3 precursor controlled by β3GNT5 is a glycolipid precursor for this 
fucosylated epitope (Fig. 5B). It is possible that the recognition epitope formerly 
attributed to the entire SSEA-1 epitope is limited to Lc3, and hence relies on a functional 
B3gnt5. 
 
Finally, the discrepancy in the time of lethality between the Ugcg null and the mice 
missing down stream enzymes like B3gnt5 is not clear. Clearly the existence of 
homologous genes which can code for compensating or competing enzymes has to 
continue. Additional investigations must also be done to clarify the issue of alternative 
substrates which might be modified by β3GNT5. If this gene is expressed continuously 
in the pre-implantation embryo, its source must be clarified. The question of whether a 
maternal transcript is involved remains. In addition β3GNT5 may be active in cascades 
other than Lc3 synthesis. However, even if Lac-Cer is its only acceptor substrate, any 
products relying on this glycolipid structure will suffer from its loss. Neither the absence 
of lactoseries glycolipids nor the accumulation of ceramide metabolites has been shown 
to lead to the lethal phenotypes observed. Before a the molecular mechanism causing the 
embryonic deaths of these mice can be described and documented, a connection between 
the activity of these genes, their products, and the observed phenotypes has to be 
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Figure 1: Glycolipid biosynthesis based on the Gal-Cer and Glc-Cer core 
substrates 
Glycolipids with the Lac-Cer core structure can be further divided after the modification 
of the Lac substrate into globo-series, lacto-series, and ganglio-series glycolipids. Notice 
that an alternative modification of the globo-series precursor is possible to give rise to 
the Gb4 structure. The B3gnt5 gene investigated in this study codes for the β3GNT5 
glycosyltransferase which catalyses the first step in lacto-series biosynthesis by adding a 
β1,3-GlcNac residue to the Gal terminal glycan of the Lac-Cer substrate. 
 
 
Figure 2: Schematic depiction of the wildtype B3gnt5 coding exon and the design 
of the targeting vector used to disrupt B3gnt5 
The targeting vector was obtained by cloning a neor sequence cassette into the coding 
exon of B3gnt5. 
 
 
Figure 3: Genomic southern and PCR genotyping B3gnt5 and B3gnt5 null alleles 
A. A probe cut from the genomic sequence of B3gnt5 was used to identify the wildtype 
vs. the null alleles. ES cells which screened positive for neor in selective media and via 
PCR for the homologous recombination of the null allele were digested with Eco RI and 
probed to reveal the single insertion site of the targeting vector and the appropriate 
change in size. The null allele revealed a signal at 2.6 kbp while the wildtype allele gives a 





B. PCR was used to genotype viable offspring, E10 embryos, and E3.5 embryos. The 
primers used for amplifying the wildtype and null fragments of DNA obtained from 
viable pups and E10 embryos are shown in the top gel. The smaller fragments amplified 
using a separate set of primers from the DNA isolated from E3.5 embryos are shown in 
the bottom gel 
 
 
Figure 4: RNA in situ hybridization of B3gnt5 expression in embryos at various 
pre-implantation stages. 
Sense and antisense RNA probes were made with a DIG label as described. All stages of 
the murine embryo show expression of B3gnt5 preceding implantation into the uterus. 
The pictures show embryos taken from C57Bl/6 wildtype matings. There is definite 
constant expression of B3gnt5 transcript at all stages preceding uterine implantation.  
 
 
Figure 5: Summary of disrupting glycolipid modifying enzymes in vivo 
A. The embryonic phenotypes observed in mice with gene disruptions that code for 
enzymes in the glycolipid biosynthetic pathway are variable. The cumulative effects we 
would assume to occur based on the cascade in which these enzymes functions leaves us 








B. The SSEA-1 embryonic epitope is dependent on the Lc3 core synthesized by the 
glycosyltransferase coded for by B3gnt5. Interestingly; the loss of its terminal fucose does 
not lead to any abnormalities in vivo. This suggests that an underlying structure is 








































WT (+/+) Het (+/-) KO (-/-) Total 
screened 
Blastocyst (E3.5) 20.8% 79.2% 0  48 
Embryo (E10) 27.4% 72.5% 0 51 
Viable pups 34% 66% 0 205 
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Figure 3 Biellmann et. al.
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KO ? Globo-series (Gb4)
Lacto-series (Lc3)
Ganglio-series (GM2/GD2)
KO dies < E4.5
KO no embryonic
death




















The recipes for the buffers mentioned in the in situ protocol are as follows: 
 





50 ug/ml E.coli tRNA 
60 mM citric aid 
In DEPC water 
Filter 0.22 μM 
 
 
Wash Buffers: store aliquots at -20°C 
Solution I 
50% formamide 
5x  SSC 
37 mM citric acid 
38 1% SDS 
39 In DEPC water and filter as above 
 
Solution II 
 50% formamide 
 2x  SSC 
93 mM citric acid 
94 0.2% SDS 
95 0.1% Tween-20 








MAB Buffer (100ml): store aliquots at 4°C for 2-3 weeks  
 1.16 g maleic acid 
 1.74 g NaCl 
 0.7 g NaOH 
 0.1 ml Tween-20 
 Bring pH to 7.5 with NaOH  and filter 
 
Alkaline Phosphatase Buffer:  FRESH  
 100 mM Tris-Cl pH 9.5 
 100 mM 5M NaCl 
 50 mM MgCl2 
 0.1% Tween-20 
 1% 100x levamisole 





Discussion and Conclusions 
1. Discussion 
 
Glycans impart greater complexity to the molecules they decorate than any other known 
modification. In essence, glycans diversify an already diverse set of proteins, lipids and 
other biological molecules. However, as with other biological systems, a certain amount 
of redundancy occurs. For glycosylation this is evident in each family of genes which 
catalyze the same linkages between the same donor and acceptor substrate units, as well 
as recycling of specific monosaccharide combinations with one another or other acceptor 
substrates. The connection between the proteome and the genome offered the first 
central dogma in Biology and is one example of how the proper function of two 
biological systems is inter- related and crucial to life. As more information and 
technologies become available to study glycans, glycomics will mature and offer an 
additional biological system to consider (fig.12) when profiling cellular and molecular 
interactions in vivo. The connection among glycome, proteome, and genome can offer us 































Figure 12: The interaction of genome, proteome, and glycome drives evolution. 
The layered depiction of the relationship among the genome, glycome, and proteome represents their dependence 
upon one another over time. At the same time, the rates at which these three systems evolve over time 
necessarily differ due to their interactions. None of them actually ever stop ‘evolving’, but the proteome will always 
change in response to the genome which in turn responds to environmental pressures (perhaps due to glycome 
interactions) and/or spontaneous mutations. The glycome has the most contact with the environment in its 
interactions with pathogens. These systems have to work in sync to provide the best adaptation of an individual to 









Least contact with environment
Most interaction with environment
Interacts with many pathogens
Regulates intra/intercellular signaling
Affected by genome and protein changes
Connects glycome and genome
Directly affected by genome changes











Discussion and Conclusions 
To date, the ABO histo-blood group antigens (HBGAs) are probably the most studied 
glycan epitopes and can be used as an example to illustrate the interaction of the genome, 
proteome, and glycome. The ABO gene locus enables the production of the ABO 
antigens. There are three main allelic forms of the ABO gene locus. The A and B alleles 
control the expression of a GT, which catalyzes the addition of the final sugar residues 
specific to the A and B antigens. The A/B polymorphism is the result of four single 
nucleotide differences coded for in the ABO gene loci. These differences lead to the A 
and/or B specific GTs which only differ from each other by a few amino acids. In the 
case of the A antigen, the GT is an α1,3-GalNAc-transferase while for the B antigen it is 
an α1,3-Gal-transferase. In the rare event that alleles for both GTs are present, an AB 
phenotype is possible. The O antigen results when the GT is inactive and thus leaves the 
precursor H antigen unmodified. ABO antigens are found attached to oligosaccharides 
on glycoproteins and glycolipids that protrude to the surface of the red blood cells 
(RBCs) (fig.13). Finally, the HBGAs include other antigens coded for by the Lewis and 








































Figure 13: The ABO blood group structures. 
The different structures of the ABO blood groups give them their serological specificities making them specific 
ligands for invading pathogens. The O antigen results from the unmodified precursor, H antigen. For A and B a GT 
resulting from the ABO gene polymorphic locus catalyzes the addition of the GalNAc and Gal, respectively, giving 
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Figure 14: Glycan structure of the human HBGAs. The HBGAs are made up of the Lewis, secretor and ABO 
gene families. GTs control the synthesis of these antigens. Different expression of the GTs from the ABO 
polymorphic gene locus are predetermined, and specific to the individual. Since three gene families modulate the 
expression of the antigens, it is a highly diverse system with numerous combinatorial possibilities. (Taken from [1]. 
 
In an elegant mathematical model evolution of the ABO polymorphism is accounted for 
via intracellular and extracellular pathogen exposure [2]. In their model Seymor et al. (2004) 
show how the ABO polymorphism could have evolved, and account for the distribution 
of the four different phenotypes (A, B, O, AB) in the human population. The non-
functional O allele is particularly striking as it is a selection for a ‘loss of function’ by not 
coding for a GT. While A and B antigen hosts readily produce antibodies against B and 
A antigens, respectively, both produce no natural antibodies towards the O antigen. The 
effects of intracellular and extracellular pathogens drive the ABO gene locus to different 
selective pressures. In the Seymor et al. (2004) model, for example, bacteria will adapt to 
rare host phenotypes or host alleles. This is a consequence of bacteria adapting more 
quickly to common host phenotypes and thus creating a frequency-dependent selection 
for rarer phenotypes and alleles. This helps maintain host polymorphism since several 
mutational changes are needed for the bacteria to adapt to particular host genotypes. 
Selective infections associated with bacteria can occur when these bacteria or their toxins 
use host glycans like the ABO antigens as entry sites for infection. Evidence for this 
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hypothesized glycan interaction comes from susceptibility studies in which a higher or 
lower rate of infection was correlated to the expression of the A, B, or O blood antigens. 
Although the molecular mechanisms behind these phenomena are not described, this  list 
includes some of the historically most deadly bacteria such as Vibrio cholerae [3, 4] and 
Shigella [5]. 
 
For intracellular pathogens like viruses, it has been suggested that they can carry ABO 
antigens as part of their envelopes after infecting a host [6-9]. Hence, a virus released 
from an A host, carries A antigens, and will be recognized by the natural immune 
systems of O and B but not by A and AB hosts. However, viruses released from an O 
host are virtually unrecognizable by any immune system since O hosts lack terminal 
glycosylation. This means that a virus from an O host is more easily transmitted to A, B, 
or AB hosts than vice versa. As a result, host A, B, or O antigen expression can lead to 
different transmission rates among a host species depending on the specific antigen 
expressed by the virus and the host. A specific example of how a virus uses the ABO 
antigens as entry ports follows below. The point is, the ABO blood group system as we 
know it today protects subsets of individual of the population from transmitting 
infections caused by enveloped viral pathogens [8]. This interaction between pathogen 
and host carries consequences for both, as they are engaging in a race to survive. 
 
The Norwalk virus (NV) has made use of histo-blood antigens as ligands for its target 
host cells and its molecular mechanism described. As mentioned the HBGAs include the 
ABO gene locus, the Lewis, and secretor gene families (for review see [10-12]). All of 
these are glycan structures (fig. 15). As a result certain individuals are at risk of being 
infected by certain strains of NV while others are not. The implication of the genetic 
factor in the infection rate of this virus was  the focus of a study in the 1970’s [1, 13].  
For the first time it was shown that genetic factors in addition to acquired immunity was 
what predisposed a host for infection. Figure 15 illustrates how the NV is believed to 
interact with the HBGAs allowing for its specificity. The eight known binding patterns 
can be divided into two groups; the A/B and the Lewis (non-secretor) groups. This 
means all NV strains in the A/B binding group bind type A and/or B and O-saliva of the 
secretors, but not to the saliva of non-secretors. All NV strains in the Lewis group bind 
HBGAs of the non-secretors and type O-secretors with weak to no binding to type A or 
B secretors.  Since the two groups mutually exclude A/B or the Lewis epitopes it is likely 
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that they represent two genetic lineages that evolved together with their human host 




Figure 15: Model for six of the eight NV interactions with the HBGAs based on the Lewis and A/B groups. 
The structure on the top right shows a pentasaccharide final structure (ALeb or BLeb) of human HBGAs. Thirteen 
NV strains are indicated based on their relative interactions with the A/B H and Lewis epitopes. (Taken from [1]) 
 
 
For all their catalytic specificity, the GTs that control glycosylation are part of a biological 
system that drives diversity. The delicate balance necessary to provide an organism with 
the glycosylation it needs to survive and reproduce, while protecting it from a changing 
pathogenic environment is an enormous challenge. If we consider all of the functions 
glycans have within a complex multicellular organism and with other organisms the 
individual may come into contact with, the fine tuned nature of glycosylation becomes 
evident. Research has shown that glycans are extremely diverse, but also that the 
expression of certain glycans can be extremely specific and developmentally limited [14, 
15]. The fetal and adult i and I antigens, respectively, discussed in the introduction are 
just one example of developmentally regulated glycan expression in mammals. How and 
why certain glycosylation patterns are so highly conserved if they are potential binding 
sites for pathogens is debatable and discussed briefly below. However, keeping as many 
variations as possible open for selection is advantageous for effective and 
‘multidirectional’ evolutionary adaptation for the entire species.  
 
Generally we distinguish between the glycans expressed on the cell surface and those 
within the cell. Even though glycans are common ligands for pathogen entry into the cell, 
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individual cell types have come to rely on specific glycans for their endogenous 
functions. Glycans within the cell often direct cell-type specific processes essential to cell 
survival. Disruption of these glycans can result in cell-specific defects. In humans a 
specific subset of genetic diseases called Congenital Defects of Glycoslyation (CDG) can 
result when the glycosylation machinery is somehow disrupted [16-21]. The effects of 
disrupting GTs involved in normal glycosylation pathways varies significantly among the 
various types of CDG described thus far. Patients may suffer from very mild to lethal 
phenotypes [22-25]. In addition other defects such as a loss of certain T-cell subsets and 
blood coagulation problems in mice missing a specific Sia-transferase [26]. This makes it 
difficult for certain glycan moieties to be discarded simply as a response to pathogen 
binding.   
 
Since each cell type is dependent on the expression of a regulated and cell-type specific 
set of genes encoding GTs, these by definition must be evolutionarily favorable. 
Variations within a species exist, such as the ABO antigens in humans and primates, but 
tend to be limited. The glycan modification of conserved glycoproteins among related 
species may vary considerably [27]. Interspecies variations are generally more striking 
than intraspecies variation. Moreover, glycans can be eradicated from a species’ 
repertoire completely. This was the case with terminal α-Gal epitopes in old world 
monkeys, apes and humans [28, 29] and the loss of N-glycolylneuraminic acid in humans 
[30]. This kind of dramatic loss precludes a superfluous or very well adapted alternative 
glycan taking over the function of the eliminated glycans.  
 
Pathogens’ ability to exploit or evolve to mimic or ‘abuse’ the glycans available in the 
host seems infinitely more likely than a complex multicellular organism constantly 
changing its glycome profile. However, Varki suggests that this is exactly what is 
happening. In his ‘Red Queen effect’ [8, 31] theory- a reference to the Red Queen in L. 
Carroll’s Through the Looking Glass- Varki argues that the glycosylation within a particular 
individual is constantly being tampered with by parasitic, bacterial, and viral invaders. In 
order to keep up, these organisms must constantly evolve their glycome. The Red Queen 
tells Alice “it will take all the running you can do, to keep in the same place”. Varki 
suggests that the glycome must constantly be changing and/or evolving effectively 
because it is in fact so dynamic. This necessarily affects evolution of the species (fig. 16). 
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Host with altered 
glycans survives
Host glycans mediate intrinsic
functions and pathogen binding
Pathogens evolve to
bind host glycans
Host recognizes pathogen glycans as ‘Non-self’
 
Figure 16: The Red Queen Effect according to Varki.(adapted from [31]) The circling arrows represent a 
potentially endless cycle between rapidly evolving potential pathogens and their target hosts. Although the host 
relies on glycans for proper endogenous functions, the host has to change them to evade pathogens glycan 
binding properties. Ideally these glycan ‘adaptations’ do not affect host cells function. Additionally hosts can 
synthesize decoys to divert pathogens away from cell surfaces. Normally, pathogen-specific glycans are 
recognized as ‘nonself’. However, pathogens alter their surface glycans in an effort to mimic those found in the 
host (‘self’). There are also possible Red Queen effects which involve host glycan binding proteins that recognize 






Discussion and Conclusions 
2. Concluding remarks to GTs and the B3gnt1 and B3gnt5 null mice 
 
Each member of the B3gnt gene family is described as having a preferred acceptor 
substrate. The phenotypic effects we expect when disrupting a specific GT are largely 
based on what we know about the expression of these acceptor substrates. We have 
observed the effects of disrupting B3gnt1and B3gnt5 in vivo in the murine model. Our 
results suggest that broader substrate specificity does not mean a more pronounced 
phenotypic effect should be expected. On the other hand, narrow substrate specificity 
does not imply a minimal phenotypic effect. This paradox underlines the importance of 
GTs and their products in vivo. These findings corroborate the idea that it is very difficult 
to predict the effects of altering glycosylation [32]. More importantly, GT activity can be 
developmentally indispensable [26, 33, 34] as in the case of B3gnt5. Table 2 below 
summarizes the phenotypes described for null mutant mice for various members of the 
B3gnt family. 
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All adult tissues  
1. Axon pathfinding in 
olfactory neurons 
disturbed [35] 
2. Affects migration rate 
of GnRH-neurons [36] 
3. Impaired male sexual 













1. higher in vivo rolling 
velocities of B and T 
lymphocytes 































Mucins in stomach, 
colon, and small 
intestine 
Important for the 
modification of O-glycans 
which modulate 
susceptibility to colorectal 
tumors and colitis [38] 
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What makes it so difficult to predict phenotypes for GT disrupted mice? Like other 
enzymes which control the synthesis of protein and lipid modifying moieties, GTs 
mediate the production of complex structures throughout the entire organism. The effect 
of disrupting the activity of a single GT is two-fold since it is responsible for the 
modification of additional molecules. First, the loss of the modifying glycan can affect 
the interactive capabilities of the acceptor substrate. The avidity of the glycan hence plays 
a role in the phenotype dependent on GT activity. Just like antibody ligand epitopes, 
carbohydrates may be visible to their interactive ligand via very specific or more general 
features. As a result, only the specific disruption of this interacting structure will lead to a 
disturbance in the signaling cascade for the acceptor substrate. At the same time, the 
recognition structure may still be functional if it is independent of the sugar moiety under 
the control of the dysfunctional GT. Secondly; the acceptor substrate may or may not be 
modified by an alternative GT. Since there are multiple genes encoding enzymes with the 
same catalytic activity with the same donor and acceptor substrates, it is possible that 
some compensation can occur from a GT from the same family (fig. 17). However, the 
competitive activity of a GT with alternative donor specificity cannot be ruled out in the 
event of a gene disruption. Moreover, the data on acceptor substrate specificity for each 
GT may not be complete. GTs may have activities beyond those recognized from 
biochemical in vitro studies. Consequently the phenotypes we observe are often very 
















































Figure 17: Acceptor substrate competition among GTs in vivo. Under wildtype conditions, the competing GTs 
are defined. There are several scenarios that can occur in vivo when a single GT is disrupted. Either there is a 
loss of the specific glycan moiety under the control of the disrupted GT, or another GT becomes active in its place. 
These new competing enzymes can either have the same catalytic activity (GT1b) or another one (GT3). As a 
result the effect of the disrupted GT (GT1) can range from no effect to very severe. The production of a new 
glycan structure due to new competing enzymes can have serious consequences for the acceptor substrates and 
their interacting partners. 
 
All of these factors have to be considered when analyzing a GT null mouse. In B3gnt1 
null mice, we were able to show the loss of lactosamine chains in the OE, VNO, and T-
cells in [35, 36]. However, this seemed to be developmentally limited to young mice. 
Henion et al. (2006) showed that lactosamines repopulated the olfactory bulb (OB) after 
postnatal day 15, suggesting a compensatory activity of another protein from the B3gnt 
gene family. Nevertheless, the initial complication in OB innervation and subsequent 
decreases in the repertoire of odorant receptors may contribute to the long term 
behavioral defects we observed in murine male sexual behavior. In addition to the 
abnormal sexual behavior of the males, another behavioral phenotype was observed in 
the B3gnt1 null female mice. They were often seen eating viable new born offspring. 
Although this behavior was not specifically investigated, it was regularly observed. It is 
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deficit similar to the one detected in the null males. This might have compounded the 
problems we had breeding the null animals. 
 
The pre-implantation embryonic lethal phenotype observed when B3gnt5 was disrupted 
came quite unexpectedly. Mice missing the glucosylceramide transferase (Ugcg), a gene 
responsible for providing the precursor for Lc3 synthase, also caused embryos to die. 
However, the embryos were viable until E6.5-7.5 [39, 40]. However, while we show 
continuous expression of B3gnt5 at all stages leading up to the blastocyst Yamishita et al. 
describe a lack of expression of Ugcg at the 2 and 4-cell stage although they claim it is 
present in unfertilized eggs. There are many ways to interpret these two apparently 
conflicting results if we assume maternal mRNA encoding β3GNT5 is not interfering,   
but some are more likely. First, there is an unknown homolog for Ugcg being expressed in 
the mice missing this gene. Secondly, β3GNT5 is acting on pre-existing glucosylceramide 
obtained from the parents. Thirdly, the possibility of additional activity of the β3GNT5 
on another substrate cannot be excluded at this time. However, mice missing other 
glycolipid synthase genes have been described which are lethal before E3.5 [41]. In the 
case of Gb4 synthase the Glc-Cer structure is also necessary for the activity of the Gb4 
synthase. There are many unanswered questions when it comes to the functions of 
glycolipids in vivo. Clearly we have only scratched the surface in this complex and 
relatively young field. Until we can describe all glycolipids and identify the genes which 
modify them it will be difficult to interpret the results we have obtained from murine 
models so far. Perhaps the lethal phenotype we observed in the B3gnt5 null mice is not 
linked to the synthesis of glycolipids at all. Further investigations of the catalytic targets 
and expression of B3gnt5 are necessary to examine these hypotheses. 
 
Mice with inactivated GTs have shown that GTs are not just interchangeable isozymes 
[35, 42-50]. However, the fine line that gives each GT its specific role in vivo is still poorly 
understood. To study the GTs effectively, closer examination of the mechanisms 
controlling their expression and their acceptor substrates will be necessary before null 
mice can be conclusively fully phenotyped. Both in vitro biochemical studies and breeding 
of viable GT null mice with other null models for suspected interactive partners could 
provide insights into specific GT activity. Furthermore, breeding mice which are null for 
two different members of the same GT family might also give us a better idea of which 
enzymes can and will compensate if one is rendered dysfunctional. GTs mediate the 
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production of a highly diverse set of biological structures. Unraveling this complexity 
requires continued systematic in vitro and in vivo investigations. 
101
Discussion and Conclusions 
1. Tan, M. and X. Jiang, Norovirus and its histo-blood group antigen receptors: an answer to a 
historical puzzle. Trends Microbiol., 2005. 13(6): p. 285-293. 
2. Seymour, R.M., M.J. Allan, A. Pomiankowski, and K. Gustafsson, Evolution of the 
human ABO polymorphism by two complementary selective pressures. Proceedings of the 
Royal Society B: Biological Sciences, 2004. 271(1543): p. 1065-1072. 
3. Glass, R.I., et al., Predisposition for cholera of individuals with O blood group. Possible 
evolutionary significance. Am. J. Epidemiol., 1985. 121(6): p. 791-6. 
4. Swerdlow, D.L., et al., Severe life-threatening cholera associated with blood group O in Peru: 
implications for the Latin American epidemic. J. Infect. Dis., 1994. 170(2): p. 468-72. 
5. Sinha, A.K., et al., Blood group and shigellosis. J. Assoc. Physicians India, 1991. 39(6): 
p. 452-3. 
6. Springer, G.F., Influenza virus vaccine and blood group A-like substances. Transfusion 
(Paris). 1963. 3: p. 233-6. 
7. Springer, G.F. and R. Schuster, [Blood Group a-Like Forssman Antigens in Myxoviruses 
Cultured in a Chicken Egg: Their Possible Pathogenetic Significance in Vaccines.]. Klin. 
Wochenschr., 1964. 42: p. 821-3. 
8. Gagneux, P. and A. Varki, Evolutionary considerations in relating oligosaccharide diversity 
to biological function. Glycobiology, 1999. 9(8): p. 747-755. 
9. Preece, A.F., K.M. Strahan, J. Devitt, F. Yamamoto, and K. Gustafsson, 
Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization 
in the presence of serum containing specific natural antibodies and complement. Blood, 2002. 
99(7): p. 2477-82. 
10. Marionneau, S., et al., ABH and Lewis histo-blood group antigens, a model for the meaning 
of oligosaccharide diversity in the face of a changing world. Biochimie, 2001. 83(7): p. 565-
73. 
11. Seltsam, A., M. Hallensleben, A. Kollmann, and R. Blasczyk, The nature of diversity 
and diversification at the ABO locus. Blood, 2003. 102(8): p. 3035-3042. 
12. Le Pendu, J., N. Ruvoen-Clouet, E. Kindberg, and L. Svensson, Mendelian 
resistance to human norovirus infections. Semin. Immunol., 2006. 18(6): p. 375-86. 
13. Parrino, T.A., D.S. Schreiber, J.S. Trier, A.Z. Kapikian, and N.R. Blacklow, 
Clinical immunity in acute gastroenteritis caused by Norwalk agent. N. Engl. J. Med., 1977. 
297(2): p. 86-9. 
14. Piller, F., et al., Biosynthesis of blood group I antigens. Identification of a UDP- 
GlcNAc:GlcNAc β1-3Gal(-R) β1-6(GlcNAc to Gal) N- acetylglucosaminyltransferase in 
hog gastric mucosa. J. Biol. Chem., 1984. 259(21): p. 13385-13390. 
15. Kingsley, P.D., K.G.T. Hagen, K.M. Maltby, J. Zara, and L.A. Tabak, Diverse 
spatial expression patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyl-transferase 
family member mRNAs during mouse development. Glycobiology, 2000. 10(12): p. 1317-
1323. 
16. Aebi, M., et al., Carbohydrate-deficient glycoprotein syndromes become congenital disorders of 
glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS. 
Glycoconj. J., 1999. 16(11): p. 669-71. 
17. Freeze, H.H., Congenital Disorders of Glycosylation: CDG-I, CDG-II, and beyond. Curr 
Mol Med, 2007. 7(4): p. 389-96. 
18. Eklund, E.A. and H.H. Freeze, The congenital disorders of glycosylation: a multifaceted 
group of syndromes. NeuroRx, 2006. 3(2): p. 254-63. 
19. Freeze, H.H. and M. Aebi, Altered glycan structures: the molecular basis of congenital 
disorders of glycosylation. Curr. Opin. Struct. Biol., 2005. 15(5): p. 490-8. 
20. Grubenmann, C.E., et al., ALG12 mannosyltransferase defect in congenital disorder of 
glycosylation type lg. Hum. Mol. Genet., 2002. 11(19): p. 2331-9. 
102
Discussion and Conclusions 
21. Aebi, M. and T. Hennet, Congenital disorders of glycosylation: genetic model systems lead the 
way. Trends Cell Biol., 2001. 11(3): p. 136-41. 
22. Kranz, C., et al., CDG-Id in two siblings with partially different phenotypes. Am J Med 
Genet A, 2007. 143(13): p. 1414-20. 
23. Kranz, C., et al., Expanding spectrum of congenital disorder of glycosylation Ig (CDG-Ig): 
sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomyopathy, genital 
malformations, and early lethality. Am J Med Genet A, 2007. 143(12): p. 1371-8. 
24. Leroy, J.G., Congenital disorders of N-glycosylation including diseases associated with O- as 
well as N-glycosylation defects. Pediatr. Res., 2006. 60(6): p. 643-56. 
25. de Lonlay, P., et al., A broad spectrum of clinical presentations in congenital disorders of 
glycosylation I: a series of 26 cases. J. Med. Genet., 2001. 38(1): p. 14-9. 
26. Lowe, J.B. and J.D. Marth, A genetic approach to mammalian glycan function. Annu. 
Rev. Biochem., 2003. 72(1): p. 643-691. 
27. Gagneux, P. and A. Varki, Evolutionary considerations in relating oligosaccharide diversity 
to biological function. Glycobiology, 1999. 9(8): p. 747-55. 
28. Koike, C., et al., Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase 
gene in higher primates. J. Biol. Chem., 2002. 277(12): p. 10114-10120. 
29. Koike, C., et al., Functionally important glycosyltransferase gain and loss during catarrhine 
primate emergence. Proc. Natl. Acad. Sci. U. S. A., 2007. 104(2): p. 559-564. 
30. Angata, T. and A. Varki, Chemical diversity in the sialic acids and related alpha-keto acids: 
an evolutionary perspective. Chem. Rev., 2002. 102(2): p. 439-69. 
31. Varki, A., Nothing in glycobiology makes sense, except in the light of evolution. Cell, 2006. 
126(5): p. 841-845. 
32. Varki, A., Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 
1993. 3(2): p. 97-130. 
33. Schwarzkopf, M., et al., Sialylation is essential for early development in mice. Proc. Natl. 
Acad. Sci. U. S. A., 2002. 99(8): p. 5267-70. 
34. Esko, J.D. and S.B. Selleck, Order out of chaos: assembly of ligand binding sites in heparan 
sulfate. Annu. Rev. Biochem., 2002. 71: p. 435-71. 
35. Henion, T.R., et al., β1,3-N-acetylglucosaminyltransferase 1 glycosylation is required for 
axon pathfinding by olfactory sensory neurons. J. Neurosci., 2005. 25(8): p. 1894-1903. 
36. Bless, E., D. Raitcheva, T.R. Henion, S. Tobet, and G.A. Schwarting, Lactosamine 
modulates the rate of migration of GnRH neurons during mouse development. Eur. J. 
Biochem., 2006. 24(3): p. 654-660. 
37. Mitoma, J., et al., Critical functions of N-glycans in L-selectin-mediated lymphocyte homing 
and recruitment. Nat Immunol, 2007. 8(4): p. 409-18. 
38. An, G., et al., Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-
derived O-glycans. J. Exp. Med., 2007. 204(6): p. 1417-29. 
39. Yamashita, T., et al., A vital role for glycosphingolipid synthesis during development and 
differentiation. Proc. Natl. Acad. Sci. U. S. A., 1999. 96(16): p. 9142-9147. 
40. Yamashita, T., R. Wada, and R.L. Proia, Early developmental expression of the gene 
encoding glucosylceramide synthase, the enzyme controlling the first committed step of 
glycosphingolipid synthesis. Biochim. Biophys. Acta, 2002. 1573(3): p. 236-40. 
41. Vollrath, B., K.J. Fitzgerald, and P. Leder, A murine homologue of the drosophila 
brainiac gene shows homology to glycosyltransferases and is required for preimplantation 
development of the mouse. Mol. Cell. Biol., 2001. 21(16): p. 5688-5697. 
42. Sheikh, K.A., et al., Mice lacking complex gangliosides develop Wallerian degeneration and 
myelination defects. Proc. Natl. Acad. Sci. U. S. A., 1999. 96(13): p. 7532-7537. 
43. Akama, T.O., et al., Essential and mutually compensatory roles of α-mannosidase II and α-
mannosidase IIx in N-glycan processing in vivo in mice. Proc. Natl. Acad. Sci. U. S. A., 
2006. 103(24): p. 8983-8988. 
103
Discussion and Conclusions 
44. Demetriou, M., M. Granovsky, S. Quaggin, and J.W. Dennis, Negative regulation of 
T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature, 2001. 409(6821): p. 
733-9. 
45. Furukawa, K., et al., Novel functions of complex carbohydrates elucidated by the mutant mice 
of glycosyltransferase genes. Biochim. Biophys. Acta, 2001. 1525(1-2): p. 1-12. 
46. Granovsky, M., et al., Suppression of tumor growth and metastasis in Mgat5-deficient mice. 
Nat. Med., 2000. 6(3): p. 306-312. 
47. Ioffe, E. and P. Stanley, Mice lacking N-acetylglucosaminyltransferase I activity die at mid- 
gestation, revealing an essential role for complex or hybrid N-linked carbohydrates. Proc. Natl. 
Acad. Sci. U. S. A., 1994. 91(2): p. 728-732. 
48. Stanley, P. and E. Ioffe, Glycosyltransferase mutants: key to new insights in glycobiology. 
FASEB J., 1995. 9(14): p. 1436-1444. 
49. Lu, Q. and B. Shur, Sperm from beta 1,4-galactosyltransferase-null mice are refractory to 
ZP3-induced acrosome reactions and penetrate the zona pellucida poorly. Development, 
1997. 124(20): p. 4121-4131. 
50. Kudo, T., et al., Normal embryonic and germ cell development in mice lacking α1,3-
Fucosyltransferase IX (Fut9) which show disappearance of stage-specific embryonic antigen 1. 




Name:    Franziska Biellmann        
Address:  Zollikerstrasse 155 
  8008 Zurich  
Birth date: 25. 06.1975 




University and College Education                                 
 
2007  Submission of Dissertation (Dr. sc. nat.) 
  “Studying the role of β1,3-N-acetylglucosaminyltransferases in the   
  mouse” 
 
2002- date:   Biological Sciences PhD Student (Dr. sc. nat.)  
  Institute for Physiology, University of Zurich 
  Prof. Dr. T. Hennet  
 
9.2000   Masters Thesis (Grade: 1.5 very good)  
  Institute for Transplantation Immunology University of   
  Heidelberg, Germany (Prof. Dr. med P. Terness) 
  „Development of an Affinity Chromatography Column for the   
  One-Step Purification of gp96 with Single-Chain Antibodies“ 
 
9.98- 9.2000  Masters Degree Program (MSc), Mannheim University of Applied  
  Sciences/ University of Heidelberg, Germany 
  Branch of study: Biotechnology  Major:  Biomedical Sciences   
 
2.94-6.97        Bachelor of Science (BSc) University of Georgia 
  Athens, GA. USA 




5.1993  High School Diploma  
  International Baccalaureate (Bilingual English/German) 
  Graduated first in class 
9.1991-5.93   Atlanta International School Atlanta, GA USA         
 
9.1989-6.91        The Galloway School Atlanta, GA USA 
         





1. Henion, T.R., Raitcheva, D., Grosholz, R., Biellmann, F., Skarnes, W.C., Hennet, T., 
Schwarting, G.A. (2005). "β1,3-N-Acetylglucosaminyltransferase 1 Glycosylation Is 
Required for Axon Pathfinding by Olfactory Sensory Neurons J. Neurosci. 25(8): 1894-
1903. 
 
2. Biellmann, F., Henion, T., Bürki, K., Hennet, T. (accepted July 2007) “Impaired sexual 
behavior in male mice deficient for the "β1,3-N-Acetylglucosaminyltransferase –1 gene” 
Mol. Reprod. Dev. (In press) 
105
 
 
